Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 36

1.

Targeting Epidermal Growth Factor Receptor (EGFR) and Human Epidermal Growth Factor Receptor 2 (HER2) Expressing Bladder Cancer Using Combination Photoimmunotherapy (PIT).

Siddiqui MR, Railkar R, Sanford T, Crooks DR, Eckhaus MA, Haines D, Choyke PL, Kobayashi H, Agarwal PK.

Sci Rep. 2019 Feb 14;9(1):2084. doi: 10.1038/s41598-019-38575-x.

2.

Photodynamic Therapy in the Treatment of Bladder Cancer: Past Challenges and Current Innovations.

Railkar R, Agarwal PK.

Eur Urol Focus. 2018 Jul;4(4):509-511. doi: 10.1016/j.euf.2018.08.005. Epub 2018 Aug 23. Review.

PMID:
30145112
3.

Integrative analysis of the epigenetic basis of muscle-invasive urothelial carcinoma.

Sanford T, Meng MV, Railkar R, Agarwal PK, Porten SP.

Clin Epigenetics. 2018 Feb 12;10:19. doi: 10.1186/s13148-018-0451-x. eCollection 2018.

4.

Protein kinase D inhibitor CRT0066101 suppresses bladder cancer growth in vitro and xenografts via blockade of the cell cycle at G2/M.

Li QQ, Hsu I, Sanford T, Railkar R, Balaji N, Sourbier C, Vocke C, Balaji KC, Agarwal PK.

Cell Mol Life Sci. 2018 Mar;75(5):939-963. doi: 10.1007/s00018-017-2681-z. Epub 2017 Oct 25.

PMID:
29071385
5.

Leveraging a Clinical Phase Ib Proof-of-Concept Study for the GPR40 Agonist MK-8666 in Patients With Type 2 Diabetes for Model-Informed Phase II Dose Selection.

Krug AW, Vaddady P, Railkar RA, Musser BJ, Cote J, Ederveen A, Krefetz DG, DeNoia E, Free AL, Morrow L, Chakravarthy MV, Kauh E, Tatosian DA, Kothare PA.

Clin Transl Sci. 2017 Sep;10(5):404-411. doi: 10.1111/cts.12479. Epub 2017 Jul 20.

6.

Epidermal Growth Factor Receptor (EGFR)-targeted Photoimmunotherapy (PIT) for the Treatment of EGFR-expressing Bladder Cancer.

Railkar R, Krane LS, Li QQ, Sanford T, Siddiqui MR, Haines D, Vourganti S, Brancato SJ, Choyke PL, Kobayashi H, Agarwal PK.

Mol Cancer Ther. 2017 Oct;16(10):2201-2214. doi: 10.1158/1535-7163.MCT-16-0924. Epub 2017 Jun 15.

7.

Validation of a microdose probe drug cocktail for clinical drug interaction assessments for drug transporters and CYP3A.

Prueksaritanont T, Tatosian DA, Chu X, Railkar R, Evers R, Chavez-Eng C, Lutz R, Zeng W, Yabut J, Chan GH, Cai X, Latham AH, Hehman J, Stypinski D, Brejda J, Zhou C, Thornton B, Bateman KP, Fraser I, Stoch SA.

Clin Pharmacol Ther. 2017 Apr;101(4):519-530. doi: 10.1002/cpt.525. Epub 2016 Dec 10.

PMID:
27943276
8.

Blood Aspergillus RNA is a promising alternative biomarker for invasive aspergillosis.

Zhao Y, Paderu P, Railkar R, Douglas C, Iannone R, Shire N, Perlin DS.

Med Mycol. 2016 Nov 1;54(8):801-7. doi: 10.1093/mmy/myw043. Epub 2016 Jun 22.

PMID:
27335056
9.

Immune response and reactogenicity of intradermal administration versus subcutaneous administration of varicella-zoster virus vaccine: an exploratory, randomised, partly blinded trial.

Beals CR, Railkar RA, Schaeffer AK, Levin Y, Kochba E, Meyer BK, Evans RK, Sheldon EA, Lasseter K, Lang N, Weinberg A, Canniff J, Levin MJ.

Lancet Infect Dis. 2016 Aug;16(8):915-22. doi: 10.1016/S1473-3099(16)00133-X. Epub 2016 Apr 6.

PMID:
27061887
10.

An accessible pharmacodynamic transcriptional biomarker for notch target engagement.

Tanis KQ, Podtelezhnikov AA, Blackman SC, Hing J, Railkar RA, Lunceford J, Klappenbach JA, Wei B, Harman A, Camargo LM, Shah S, Finney EM, Hardwick JS, Loboda A, Watters J, Bergstrom DA, Demuth T, Herman GA, Strack PR, Iannone R.

Clin Pharmacol Ther. 2016 Apr;99(4):370-80. doi: 10.1002/cpt.335. Epub 2016 Feb 17.

PMID:
26765077
11.

Pre-vaccination inflammation and B-cell signalling predict age-related hyporesponse to hepatitis B vaccination.

Fourati S, Cristescu R, Loboda A, Talla A, Filali A, Railkar R, Schaeffer AK, Favre D, Gagnon D, Peretz Y, Wang IM, Beals CR, Casimiro DR, Carayannopoulos LN, Sékaly RP.

Nat Commun. 2016 Jan 8;7:10369. doi: 10.1038/ncomms10369.

12.

Early Clinical Detection of Pharmacologic Response in Insulin Action in a Nondiabetic Insulin-Resistant Population.

Shankar SS, Shankar RR, Railkar RA, Beals CR, Steinberg HO, Kelley DE.

Curr Ther Res Clin Exp. 2015 Aug 14;77:83-9. doi: 10.1016/j.curtheres.2015.08.001. eCollection 2015 Dec.

13.

Bayesian methods for the design and analysis of noninferiority trials.

Gamalo-Siebers M, Gao A, Lakshminarayanan M, Liu G, Natanegara F, Railkar R, Schmidli H, Song G.

J Biopharm Stat. 2016;26(5):823-41. doi: 10.1080/10543406.2015.1074920. Epub 2015 Aug 6. Review.

PMID:
26247350
14.

Correlation between Circulating Fungal Biomarkers and Clinical Outcome in Invasive Aspergillosis.

Neofytos D, Railkar R, Mullane KM, Fredricks DN, Granwehr B, Marr KA, Almyroudis NG, Kontoyiannis DP, Maertens J, Fox R, Douglas C, Iannone R, Kauh E, Shire N.

PLoS One. 2015 Jun 24;10(6):e0129022. doi: 10.1371/journal.pone.0129022. eCollection 2015.

15.

Novel anti IGFBP2 single chain variable fragment inhibits glioma cell migration and invasion.

Patil SS, Railkar R, Swain M, Atreya HS, Dighe RR, Kondaiah P.

J Neurooncol. 2015 Jun;123(2):225-35. doi: 10.1007/s11060-015-1800-7. Epub 2015 May 6.

PMID:
25944386
16.

High-dimensional analysis of the aging immune system: verification of age-associated differences in immune signaling responses in healthy donors.

Longo DM, Louie B, Ptacek J, Friedland G, Evensen E, Putta S, Atallah M, Spellmeyer D, Wang E, Pos Z, Marincola FM, Schaeffer A, Lukac S, Railkar R, Beals CR, Cesano A, Carayannopoulos LN, Hawtin RE.

J Transl Med. 2014 Jun 21;12:178. doi: 10.1186/1479-5876-12-178.

17.

Reproducibility of hepatic fat fraction measurement by magnetic resonance imaging.

Mashhood A, Railkar R, Yokoo T, Levin Y, Clark L, Fox-Bosetti S, Middleton MS, Riek J, Kauh E, Dardzinski BJ, Williams D, Sirlin C, Shire NJ.

J Magn Reson Imaging. 2013 Jun;37(6):1359-70. doi: 10.1002/jmri.23928. Epub 2012 Nov 21.

PMID:
23172799
19.

Repeatability of edited lactate and other metabolites in astrocytoma at 3T.

McLean MA, Sun A, Bradstreet TE, Schaeffer AK, Liu H, Iannone R, Herman G, Railkar RA, Joubert I, Gillard JH, Price SJ, Griffiths JR.

J Magn Reson Imaging. 2012 Aug;36(2):468-75. doi: 10.1002/jmri.23673. Epub 2012 Apr 25.

PMID:
22535478
20.

Insights into differential modulation of receptor function by hinge region using novel agonistic lutropin receptor and inverse agonistic thyrotropin receptor antibodies.

Majumdar R, Railkar R, Dighe RR.

FEBS Lett. 2012 Mar 23;586(6):810-7. doi: 10.1016/j.febslet.2012.01.052. Epub 2012 Feb 2.

21.

Docking and free energy simulations to predict conformational domains involved in hCG-LH receptor interactions using recombinant antibodies.

Majumdar R, Railkar R, Dighe RR.

Proteins. 2011 Nov;79(11):3108-22. doi: 10.1002/prot.23138. Epub 2011 Aug 30.

PMID:
21989932
22.

Evaluation of an experimental urodynamic platform to identify treatment effects: a randomized, placebo-controlled, crossover study in patients with overactive bladder.

Frenkl T, Railkar R, Shore N, Bailen J, Sutherland S, Burke J, Scott BB, Ruddy M, Beals C.

Neurourol Urodyn. 2012 Jan;31(1):69-74. doi: 10.1002/nau.21094. Epub 2011 Sep 8.

PMID:
21905086
23.

Test-retest repeatability of MR elastography for noninvasive liver fibrosis assessment in hepatitis C.

Shire NJ, Yin M, Chen J, Railkar RA, Fox-Bosetti S, Johnson SM, Beals CR, Dardzinski BJ, Sanderson SO, Talwalkar JA, Ehman RL.

J Magn Reson Imaging. 2011 Oct;34(4):947-55. doi: 10.1002/jmri.22716. Epub 2011 Jul 12.

24.

Variability of urodynamic parameters in patients with overactive bladder.

Frenkl TL, Railkar R, Palcza J, Scott BB, Alon A, Green S, Schaefer W.

Neurourol Urodyn. 2011 Nov;30(8):1565-9. doi: 10.1002/nau.21081. Epub 2011 Jun 14.

PMID:
21674594
25.

Natural history of genital warts: analysis of the placebo arm of 2 randomized phase III trials of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine.

Garland SM, Steben M, Sings HL, James M, Lu S, Railkar R, Barr E, Haupt RM, Joura EA.

J Infect Dis. 2009 Mar 15;199(6):805-14. doi: 10.1086/597071.

PMID:
19199546
26.

Baseline characteristics and prevalence of HPV 6, 11, 16, 18 in young German women participating in phase III clinical trials of a quadrivalent HPV (6/11/16/18) vaccine.

Barthell E, Woelber L, Hellner K, Camerer B, Gieseking F, Hauschild M, Mylonas I, Friese K, Sings HL, Railkar R, Gause C, Barr E.

Arch Gynecol Obstet. 2009 Jun;279(6):803-7. doi: 10.1007/s00404-008-0806-1. Epub 2008 Oct 21.

PMID:
18936950
27.

Impact of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 virus-like particle vaccine in a sexually active population of North American women.

Barr E, Gause CK, Bautista OM, Railkar RA, Lupinacci LC, Insinga RP, Sings HL, Haupt RM.

Am J Obstet Gynecol. 2008 Mar;198(3):261.e1-11. doi: 10.1016/j.ajog.2007.09.001.

PMID:
18313445
28.

Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases.

Garland SM, Hernandez-Avila M, Wheeler CM, Perez G, Harper DM, Leodolter S, Tang GW, Ferris DG, Steben M, Bryan J, Taddeo FJ, Railkar R, Esser MT, Sings HL, Nelson M, Boslego J, Sattler C, Barr E, Koutsky LA; Females United to Unilaterally Reduce Endo/Ectocervical Disease (FUTURE) I Investigators.

N Engl J Med. 2007 May 10;356(19):1928-43.

29.

Noninferiority of antibody response to human papillomavirus type 16 in subjects vaccinated with monovalent and quadrivalent L1 virus-like particle vaccines.

Garland SM, Steben M, Hernandez-Avila M, Koutsky LA, Wheeler CM, Perez G, Harper DM, Leodolter S, Tang GW, Ferris DG, Esser MT, Vuocolo SC, Nelson M, Railkar R, Sattler C, Barr E; 012 Study Investigators.

Clin Vaccine Immunol. 2007 Jun;14(6):792-5. Epub 2007 Apr 11.

30.

High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up.

Villa LL, Costa RL, Petta CA, Andrade RP, Paavonen J, Iversen OE, Olsson SE, Høye J, Steinwall M, Riis-Johannessen G, Andersson-Ellstrom A, Elfgren K, Krogh Gv, Lehtinen M, Malm C, Tamms GM, Giacoletti K, Lupinacci L, Railkar R, Taddeo FJ, Bryan J, Esser MT, Sings HL, Saah AJ, Barr E.

Br J Cancer. 2006 Dec 4;95(11):1459-66. Epub 2006 Nov 21.

31.

Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18.

Villa LL, Ault KA, Giuliano AR, Costa RL, Petta CA, Andrade RP, Brown DR, Ferenczy A, Harper DM, Koutsky LA, Kurman RJ, Lehtinen M, Malm C, Olsson SE, Ronnett BM, Skjeldestad FE, Steinwall M, Stoler MH, Wheeler CM, Taddeo FJ, Yu J, Lupinacci L, Railkar R, Marchese R, Esser MT, Bryan J, Jansen KU, Sings HL, Tamms GM, Saah AJ, Barr E.

Vaccine. 2006 Jul 7;24(27-28):5571-83. Epub 2006 May 15.

PMID:
16753240
32.

Immunogenicity and reactogenicity of a novel vaccine for human papillomavirus 16: a 2-year randomized controlled clinical trial.

Poland GA, Jacobson RM, Koutsky LA, Tamms GM, Railkar R, Smith JF, Bryan JT, Cavanaugh PF Jr, Jansen KU, Barr E.

Mayo Clin Proc. 2005 May;80(5):601-10.

PMID:
15887427
33.

Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial.

Villa LL, Costa RL, Petta CA, Andrade RP, Ault KA, Giuliano AR, Wheeler CM, Koutsky LA, Malm C, Lehtinen M, Skjeldestad FE, Olsson SE, Steinwall M, Brown DR, Kurman RJ, Ronnett BM, Stoler MH, Ferenczy A, Harper DM, Tamms GM, Yu J, Lupinacci L, Railkar R, Taddeo FJ, Jansen KU, Esser MT, Sings HL, Saah AJ, Barr E.

Lancet Oncol. 2005 May;6(5):271-8.

PMID:
15863374
34.

Early assessment of the efficacy of a human papillomavirus type 16 L1 virus-like particle vaccine.

Brown DR, Fife KH, Wheeler CM, Koutsky LA, Lupinacci LM, Railkar R, Suhr G, Barr E, Dicello A, Li W, Smith JF, Tadesse A, Jansen KU.

Vaccine. 2004 Jul 29;22(21-22):2936-42.

PMID:
15246630
35.

Simultaneous testing strategy for comparing two treatments in a stratified binomial trial.

Railkar RA, Mehrotra DV, Iglewicz B.

J Biopharm Stat. 2000 Aug;10(3):335-49.

PMID:
10959915
36.

Minimum risk weights for comparing treatments in stratified binomial trials.

Mehrotra DV, Railkar R.

Stat Med. 2000 Mar 30;19(6):811-25.

PMID:
10734285

Supplemental Content

Loading ...
Support Center